Skip to content

Nurix Therapeutics, Inc. NRIX Lease Liability Payments - Due After Year Five

Lease Liability Payments - Due After Year Five at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$1.95B+40.1%
Enterprise value$1.94B+45.1%
P/S27.2×+2.5×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive.

The official record: Nurix Therapeutics, Inc.’s 10-K, filed January 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s lease liability payments - due after year five.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s lease liability payments - due after year five?
Nurix Therapeutics, Inc. (NRIX) reported lease liability payments - due after year five of $24.63M in Q3 2025.
What does lease liability payments - due after year five mean?
Represents the total undiscounted future cash outflows required for operating and finance lease obligations beyond a five-year horizon. This metric provides visibility into long-term fixed occupancy and equipment costs, which are critical for assessing structural overhead and long-term solvency.